survival of tnf antagonists in spondylarthritis is better than in rheumatoid arthritis. data from the spanish registry biobadaser肿瘤坏死因子拮抗剂的生存在类风湿性关节炎的脊椎关节炎比。.pdfVIP

Available online /content/8/3/R72 Vol 8 No 3 Open Access Research article Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER 1 2 Loreto Carmona , Juan J Gómez-Reino and on behalf of the BIOBADASER Group 1Research Unit, Spanish Society of Rheumatology, Madrid, Spain Marques de Duero 5, 28001 Madrid, Spain 2Rheumatology Service and Department of Medicine, Hospital Clínico Universitario, Medical School, Universidad de Santiago de Compostela, Santiago de Compostela, A Choupana s/n, 15706 SantiagoSpain Corresponding author: Loreto Carmona, lcarmona@ser.es Received: 13 Jan 2006 Revisions requested: 7 Feb 2006 Revisions received: 4 Mar 2006 Accepted: 20 Mar 2006 Published: 18 Apr 2006 Arthritis Research Therapy 2006, 8:R72 (doi:10.1186/ar1941) This article is online at: /content/8/3/R72 © 2006 Carmona and Gómez-Reino; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract The aim of the present work is to compare drug survival and confidence interval [CI], 0.57–0.76) after adjustment for age, safety of infliximab, etanercept, and adalimumab (tumor necrosis gender, and use of infliximab. The difference remained after factor [TNF] antagonists) in spondylarthritis (SpA) with those of controlling for the individual medication and its place in the rheumatoid arthritis (RA).